Patient leaflets EuroGentest has developed a series of 15 leaflets to provide general information for patients and families about genetics and genetic testing. Can either be downloaded and printed out, or you can look at the information online by choosing the HTML version. Select your language (more than 30 languages are available!): • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • NEWThe Council of Europe has developed a general leaflet on Genetic Tests for Health Purposes with the support of Eurogentest and the European Society of Human Genetics (click ). Two new leaflets have been created on non-invasive prenatal testing (NIPT): One generic leaflet () and one more specific (). Direct-to-consumer genetic testing When a test is offered to patients through a private company instead of health care providers, this test is called a direct-to-consumer test (DTC). Although this makes genetic testing available for a broad audience, one must be aware of the risks and limitations of these tests when offered outside of health care.

Click for more information on DTC. NEWEuroGentest developed a simple tool for clinicians that will help them to understand and advise patients about the many issues inherent in the use of such services (click. Individuals considering using a DTC test may also find this tool useful.

Mission and Vision There is an impelling need to speed up the transfer of scientific results from the laboratory to the clinic: clinicians require it, society demands it, and scientists must respond. Each interest group depends on the other two to achieve this aim. Resetter epson l1300 trial. This is why we established the Molecular Medicine for Care (MMC) program at IEO.

Tweet with a location. You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications.

Through the mutual collaboration of scientists, clinicians and patients, we are driving discoveries from the basic research programs conducted in the laboratory of Pier Paolo Di Fiore [1-11] into the clinical domain, through four scientific programs that focus on breast, lung and ovarian cancers. While these are being carried forward, we have brewing in the pipeline a number of other new discovery projects that will ultimately translate into the improved clinical management of breast, lung, ovarian and prostate cancer. Our current scientific programs aim to: 1) Identify stem cell markers for the diagnosis, prognosis and therapeutic stratification of breast, lung and ovarian cancers. 2) Develop a blood test for the early diagnosis of lung cancer. 3) Understand breast and ovarian cancer for early diagnosis.

4) Make new discoveries to increase our molecular understanding of cancer and feed new translational research projects. MMC Scientific Programs Stem cell markers for the diagnosis, prognosis and therapeutic stratification of breast, lung and ovarian cancer Lead scientific contacts Breast cancer: Salvatore Pece, Fabrizio Bianchi, Stefano Confalonieri, Manuela Vecchi Lung cancer: Elena Belloni Ovarian Cancer: Ugo Cavallaro Stem cells are a rare population of cells necessary for tissue integrity and regeneration in case of injury. Their numbers within any normal tissue are very tightly controlled, but it is now widely accepted that these restraints can malfunction in cancer, leading to an inappropriate expansion of stem cell populations. We discovered that genes expressed in breast stem cells can be used as biomarkers to improve the stratification of breast tumors according to their pathological, molecular and clinical characteristics [3]. However, the original stem cell signature we identified contained too many genes to be of clinical use. Therefore, we are now developing a smaller stem cell profile that still retains the predictive features of the stem cell profile, but that can be analyzed more easily in a clinical setting using immunohistochemistry or quantitative PCR analysis. We are assessing the ability of these biomarkers to classify breast tumors according to aggressiveness, associated metastatic risk and therapeutic response to hormonal and/or chemo-/radio-therapy.